SCHEMBL19006515

SCHEMBL19006515

CC(C)COC(=O)c1ccnc(C(C)(C)C)c1

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JMJD6 Q6NYC1 2/20 0.56
LMNA P02545 6/20 0.49
ALDH1A1 P00352 4/20 0.49
MEN1 O00255 1/20 0.49
MAPK1 P28482 1/20 0.49
KMT2A Q03164 1/20 0.49
SMN1; SMN2 Q16637 4/20 0.47
HTT P42858 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
TSHR P16473 2/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
HSD17B10 Q99714 1/20 0.43
ADRB2 P07550 1/20 0.43
ADRB1 P08588 1/20 0.43
ADRB3 P13945 1/20 0.43
PLA2G1B P04054 1/20 0.39
ATG4B Q9Y4P1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22285883 0.82 JMJD6 (0.78) JMJD6ALDH1A1TSHR
SCHEMBL30180575 0.82 JMJD6 (0.78) JMJD6ALDH1A1TSHR
SCHEMBL19006406 0.79 L3MBTL1 (0.51) JMJD6LMNAALDH1A1MEN1MAPK1
SCHEMBL13384488 0.79 LMNA (0.57) JMJD6LMNAALDH1A1MEN1MAPK1
SCHEMBL13600637 0.78 JMJD6 (0.57) JMJD6ALDH1A1TSHRADRB2ADRB1
SCHEMBL18999248 0.77 LMNA (0.52) LMNAALDH1A1MEN1MAPK1KMT2A
SCHEMBL4102364 0.75 LMNA (0.50) LMNAALDH1A1MEN1MAPK1KMT2A
SCHEMBL11640564 0.75 ADRB2 (0.59) JMJD6LMNAALDH1A1KMT2ASMN1; SMN2
SCHEMBL109308 0.73 ALDH1A1 (0.61) JMJD6ALDH1A1KMT2ATSHRHSD17B10
SCHEMBL1759647 0.73 LMNA (0.62) JMJD6LMNAALDH1A1MEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10428076-B2 Soluble guanylate cyclase stimulators MERCK SHARP & DOHME CORP. (US) 2019-10-01 US disclosed
US-10030027-B2 Soluble guanylate cyclase stimulators MERCK SHARP & DOHME CORP. (US) 2018-07-24 US disclosed
US-20170174693-A1 SOLUBLE GUANYLATE CYCLASE STIMULATORS MERCK SHARP & DOHME LLC 2017-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170174693-A1 SOLUBLE GUANYLATE CYCLASE STIMULATORS GUCY1A1, GUCY1A2, PDE2A JMJD6 1245/4885LMNA 971/4885ALDH1A1 2472/4885
US-10030027-B2 Soluble guanylate cyclase stimulators GUCY1A1, GUCY1A2, PDE2A JMJD6 1245/4885LMNA 971/4885ALDH1A1 2472/4885
US-10428076-B2 Soluble guanylate cyclase stimulators GUCY1A1, GUCY1A2, PDE2A JMJD6 1245/4885LMNA 971/4885ALDH1A1 2472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.